
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9286081/publications.pdf Version: 2024-02-01



EMANUELE FOCÃ

#	Article	IF	CITATIONS
1	Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men. Journal of Endocrinological Investigation, 2022, 45, 433-443.	1.8	5
2	Decrease in New Diagnosis of HIV/AIDS in the Two Years Period 2019-2020: Impact of COVID-19 Pandemic. Journal of Public Health Research, 2022, 11, jphr.2021.2256.	0.5	10
3	Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects. Pharmacological Research, 2022, 176, 106064.	3.1	4
4	Explorative study regarding influenza vaccine hesitancy among HIV-infected patients. Human Vaccines and Immunotherapeutics, 2022, 18, 1-7.	1.4	0
5	Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure. Cell Reports Medicine, 2022, 3, 100560.	3.3	23
6	Psychological and Emotional Impact of COVID-19 Pandemic on People Living with Chronic Disease: HIV and Cancer. AIDS and Behavior, 2022, 26, 2920-2930.	1.4	2
7	Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy. Sexually Transmitted Infections, 2022, , sextrans-2021-055289.	0.8	1
8	Mechanical Ventilation in COVID-19 Patients: Insights into the Role of Age and Frailty from a Multicentre Observational Study. , 2022, 13, 340.		6
9	Low-dose Lung Radiotherapy for COVID-19-related Pneumonia: Preliminary Results of the Italian Mono-institutional COLOR-19 Trial. In Vivo, 2022, 36, 1959-1965.	0.6	3
10	Omicron BA.2 Lineage, the "Stealth―Variant: Is It Truly a Silent Epidemic? A Literature Review. International Journal of Molecular Sciences, 2022, 23, 7315.	1.8	17
11	HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	1
12	Clinical Presentation and Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2–Related Encephalitis: The ENCOVID Multicenter Study. Journal of Infectious Diseases, 2021, 223, 28-37.	1.9	87
13	Hypogonadism and liver fibrosis in HIV-infected patients. Journal of Endocrinological Investigation, 2021, 44, 1971-1979.	1.8	6
14	Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV. Aids, 2021, 35, 939-945.	1.0	19
15	Serological Response to SARS-CoV-2 in Health Care Workers Employed in a Large Tertiary Hospital in Lombardy, Northern Italy. Microorganisms, 2021, 9, 488.	1.6	16
16	Descriptive modification of inflammatory markers in HIV patients after cART initiation according to gender, smoking habit, CMV infection, BMI and serum lipids. Cytokine, 2021, 143, 155547.	1.4	0
17	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clinical Infectious Diseases, 2021, 73, e3019-e3026.	2.9	131
18	Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort. PLoS ONE, 2021, 16, e0258533.	1.1	0

#	Article	IF	CITATIONS
19	A 2021 Update on Syphilis: Taking Stock from Pathogenesis to Vaccines. Pathogens, 2021, 10, 1364.	1.2	19
20	Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances. Aids, 2020, 34, 53-61.	1.0	14
21	Prevalence of Non-B HIV-1 Subtypes in North Italy and Analysis of Transmission Clusters Based on Sequence Data Analysis. Microorganisms, 2020, 8, 36.	1.6	11
22	Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection. PLoS ONE, 2020, 15, e0240550.	1.1	2
23	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Journal of Translational Medicine, 2020, 18, 405.	1.8	98
24	Steroidâ€Responsive Encephalitis in Coronavirus Disease 2019. Annals of Neurology, 2020, 88, 423-427.	2.8	230
25	Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmunity Reviews, 2020, 19, 102568.	2.5	637
26	UVA1 phototherapy as a treatment option for plaque psoriasis in HIVâ€positive patients. Photodermatology Photoimmunology and Photomedicine, 2020, 36, 478-480.	0.7	2
27	Laboratory considerations amidst the coronavirus disease 2019Âoutbreak: the Spedali Civili in Brescia experience. Bioanalysis, 2020, 12, 1223-1230.	0.6	8
28	Presence of V72I, G123S and R127K Integrase Inhibitor polymorphisms could reduce ART effectiveness: a retrospective longitudinal study. HIV Research and Clinical Practice, 2020, 21, 24-33.	1.1	1
29	Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort. HIV Medicine, 2020, 21, 523-535.	1.0	6
30	Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. Kidney International Reports, 2020, 5, 580-585.	0.4	195
31	Two Xâ€linked agammaglobulinemia patients develop pneumonia as COVIDâ€19 manifestation but recover. Pediatric Allergy and Immunology, 2020, 31, 565-569.	1.1	298
32	Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. Journal of Critical Care, 2020, 58, 29-33.	1.0	130
33	Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression. Patient, 2020, 13, 375-387.	1.1	5
34	Steroid-Responsive Encephalitis in Coronavirus Disease 2019. , 2020, 88, 423.		1
35	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection–Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study. Pathogens and Immunity, 2020, 5, 8.	1.4	16
36	SARS-CoV-2 invades the West. How to face a COVID-19 epidemic in Lombardy, Northern Italy?. Infezioni in Medicina, 2020, 28, 133-134.	0.7	3

#	Article	IF	CITATIONS
37	Disengagement and reengagement of HIV continuum of care in a single center cohort in northern Italy. HIV Research and Clinical Practice, 2019, 20, 1-11.	1.1	10
38	Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPPO―Cohort. PLoS ONE, 2019, 14, e0222225.	1.1	9
39	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naÃ̄ve patients with CD4<200 cells/uL (the PRADAR study). PLoS ONE, 2019, 14, e0222650.	1.1	11
40	Impact of genotypic susceptibility score on cART outcomes during primary HIV infection. Journal of Medical Virology, 2019, 91, 1891-1895.	2.5	0
41	Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities. Aids, 2019, 33, 759-762.	1.0	19
42	Prognostic role of inflammatory biomarkers in HIVâ€infected patients with a first diagnosis of hepatocellular carcinoma: A singleâ€center study. Journal of Medical Virology, 2019, 91, 241-248.	2.5	1
43	Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV subjects on cART: A potential marker of kidney disease. Biomedical Reports, 2019, 10, 140-144.	0.9	12
44	Title is missing!. , 2019, 14, e0222650.		0
45	Title is missing!. , 2019, 14, e0222650.		0
46	Title is missing!. , 2019, 14, e0222650.		0
47	Title is missing!. , 2019, 14, e0222650.		о
48	Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience. AIDS Research and Human Retroviruses, 2018, 34, 570-574.	0.5	15
49	The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 – 74 years and more than 75 years. BMC Geriatrics, 2018, 18, 99.	1.1	117
50	Perinatally HIV-Infected Youths After Transition from Pediatric to Adult Care, a Single-Center Experience from Northern Italy. AIDS Research and Human Retroviruses, 2018, 34, 241-243.	0.5	12
51	Effectiveness of kidney transplantation in HIV-infected recipients under combination antiretroviral therapy: a single-cohort experience (Brescia, Northern Italy). Infection, 2018, 46, 77-82.	2.3	6
52	Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. Antimicrobial Agents and Chemotherapy, 2018, 62,	1.4	3
53	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 1955-1964.	1.3	29
54	Survival in <scp>HIV</scp> â€infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. HIV Medicine, 2018, 19, 523-531.	1.0	11

#	Article	IF	CITATIONS
55	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2018, 73, 177-182.	1.3	22
56	Autologous Stem Cell Transplantation Is Effective in Chemosensitive HIV-Associated Lymphoma Irrespective of Previous Therapy and Histological Subtype. Blood, 2018, 132, 2145-2145.	0.6	0
57	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). International Journal of Epidemiology, 2017, 46, dyv192.	0.9	15
58	Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2879-2886.	1.3	30
59	Comparison between the gold standard DXA with calcaneal quantitative ultrasound based-strategy (QUS) to detect osteoporosis in an HIV infected cohort. Brazilian Journal of Infectious Diseases, 2017, 21, 581-586.	0.3	18
60	Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2017, 72, 3163-3166.	1.3	6
61	Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 338-342.	0.9	9
62	Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort. BMC Infectious Diseases, 2017, 17, 212.	1.3	0
63	DISSEMINATED HISTOPLASMOSIS AS AIDS PRESENTATION. CASE REPORT AND COMPREHENSIVE REVIEW OF CURRENT LITERATURE. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 10, e2018040.	0.5	15
64	Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). Journal of Antimicrobial Chemotherapy, 2017, 72, dkw557.	1.3	62
65	Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy. International Journal of Molecular Sciences, 2016, 17, 434.	1.8	24
66	Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study. PLoS ONE, 2016, 11, e0154900.	1.1	14
67	Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 1551-1558.	0.6	30
68	Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium–long-term all-cause mortality: a MASTER cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 3519-3527.	1.3	16
69	Liver fibrosis progression and clinical outcomes are intertwined. Medicine (United States), 2016, 95, e4091.	0.4	17
70	The good, the bad and the ugly: determinants of antiretroviral-associated toxicities. Future Virology, 2016, 11, 239-243.	0.9	0
71	Host and disease factors are associated with cognitive function in European <scp>HIV</scp> â€infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 2016, 17, 471-478.	1.0	7
72	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 1056-1062.	1.3	22

#	Article	IF	CITATIONS
73	Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study). New Microbiologica, 2016, 39, 290-294.	0.1	4
74	Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART. PLoS ONE, 2015, 10, e0124741.	1.1	36
75	Long-lasting humoral immune response induced in HIV-1-infected patients by a synthetic peptide (AT20) derived from the HIV-1 matrix protein p17 functional epitope. HIV Clinical Trials, 2015, 16, 157-162.	2.0	5
76	Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study. PLoS ONE, 2014, 9, e94768.	1.1	50
77	Elderly Women With Human Immunodeficiency Virus Infection: Is There an Effect of the Virus on Neuropsychological Profile?. Journal of the American Geriatrics Society, 2014, 62, 194-196.	1.3	4
78	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology, 2014, 11, 49.	0.9	48
79	Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. Osteoporosis International, 2014, 25, 2263-2269.	1.3	17
80	Clinical and immunological outcomes according to adherence to first-line HAART in a urban and rural cohort of HIV-infected patients in Burkina Faso, West Africa. BMC Infectious Diseases, 2014, 14, 153.	1.3	16
81	Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study. Vaccine, 2014, 32, 1072-1078.	1.7	23
82	Evaluation of Boosted and Unboosted Atazanavir Plasma Concentration in HIV Infected Patients. Current HIV Research, 2014, 11, 642-646.	0.2	5
83	Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial. PLoS ONE, 2013, 8, e80157.	1.1	35
84	Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. European Review for Medical and Pharmacological Sciences, 2013, 17, 1218-32.	0.5	43
85	Kidney disease in HIV-infected patients. European Review for Medical and Pharmacological Sciences, 2013, 17, 2660-7.	0.5	29
86	MALARIA AND HIV IN ADULTS: When The Parasite runs into The Virus. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012032.	0.5	12
87	The Disagreement Among Methods to Evaluate Glomerular Filtration Rate in HIV-Infected Patients Naive to Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2012, 28, 637-640.	0.5	0
88	Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-NaÃ⁻ve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir. HIV Clinical Trials, 2012, 13, 245-255.	2.0	24
89	A Randomized, Pilot Trial to Evaluate Glomerular Filtration Rate by Creatinine or Cystatin C in Naive HIV-Infected Patients After Tenofovir/Emtricitabine in Combination With Atazanavir/Ritonavir or Efavirenz. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 18-24.	0.9	37
90	Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received. AIDS Research and Therapy, 2012, 9, 18.	0.7	11

#	Article	IF	CITATIONS
91	Unboosted Atazanavir for Treatment of HIV Infection. Drugs, 2012, 72, 1161-1173.	4.9	16
92	High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine, 2012, 41, 512-517.	1.1	52
93	Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infectious Diseases, 2012, 12, 38.	1.3	33
94	Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction?. BMC Medicine, 2011, 9, 138.	2.3	35
95	Cryptogenic Liver Diseases: Sailing by Sight from HIV Co-Infection with Hepatitis Viruses to HIV Mono-Infection Through the Pillars of Hercules. Current HIV Research, 2011, 9, 61-69.	0.2	3
96	Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection. Clinical Infectious Diseases, 2011, 52, 1164-1173.	2.9	70
97	Reply to van der Pas et al. Clinical Infectious Diseases, 2011, 53, 614-615.	2.9	1
98	Malaria Prophylaxis: A Comprehensive Review. Pharmaceuticals, 2010, 3, 3212-3239.	1.7	33
99	Phenotypic and genotypic evaluation of slime production by conventional and molecular microbiological techniques. Microbiological Research, 2009, 164, 522-528.	2.5	24
100	P. falciparum malaria recrudescence in a cancer patient. Infezioni in Medicina, 2009, 17, 33-4.	0.7	10
101	Six cases of sepsis caused by Pantoea agglomerans in a teaching hospital. New Microbiologica, 2009, 32, 119-23.	0.1	36